Coronada vaka say\u0131lar\u0131 artarken uzmanlardan da art arda uyar\u0131lar geliyor. T\u00fcrkiye Klinik Mikrobiyoloji ve \u0130nfeksiyon Hastal\u0131klar\u0131 Derne\u011fi KL\u0130M\u0130K, Covid-19\u2019a kar\u015f\u0131 g\u00fcncel ba\u011f\u0131\u015f\u0131klama \u00f6nerilerini payla\u015ft\u0131. T\u00fcm sorulara yan\u0131t olacak \u00f6neriler i\u015fte bu 16 maddede s\u0131raland\u0131.<\/b><\/p>\n
T\u00fcrk Tabipleri Birli\u011fi (TTB), TTB Uzmanl\u0131k Dernekleri E\u015fg\u00fcd\u00fcm Kurulu, Halk Sa\u011fl\u0131\u011f\u0131 Uzmanlar\u0131 Derne\u011fi, T\u00fcrk Klinik Mikrobiyoloji ve \u0130nfeksiyon Hastal\u0131klar\u0131 Derne\u011fi KL\u0130M\u0130K ile T\u00fcrk Toraks Derne\u011fi \u00fc\u00e7 g\u00fcn \u00f6nce yapt\u0131klar\u0131 ortak a\u00e7\u0131klama ile pandeminin bitmedi\u011fi uyar\u0131s\u0131 yapt\u0131.<\/p>\n
YEN\u0130 DALGA HIZLA YAYILIYOR<\/strong><\/p>\n Yeni bir dalgan\u0131n h\u0131zlanarak t\u0131rmand\u0131\u011f\u0131, vaka say\u0131lar\u0131nda \u00e7ok ciddi art\u0131\u015flara neden oldu\u011funu dile getirdi. Uyar\u0131n\u0131n ard\u0131ndan Sa\u011fl\u0131k Bakan\u0131 Fahrettin Koca’da bir a\u00e7\u0131klama yaparak vatanda\u015flar\u0131n Covid-19 a\u015f\u0131lar\u0131n\u0131n hat\u0131rlatma dozlar\u0131n\u0131 yapmalar\u0131n\u0131 istedi.<\/p>\n Sosyal medya ve uzmanlara y\u00f6neltilen kimin hangi a\u015f\u0131lar\u0131 nas\u0131l olaca\u011f\u0131yla ilgili \u00e7ok say\u0131da sorunun cevab\u0131n\u0131 KL\u0130M\u0130K verdi.<\/p>\n \u0130\u015eTE G\u00dcNCEL A\u015eILAMA \u00d6NER\u0130LER\u0130<\/strong><\/p>\n 1.\u00a0Hi\u00e7 a\u015f\u0131lanmam\u0131\u015f ki\u015filerin bir ay arayla iki doz BioNTech olduktan en erken 3 ay sonra 3. doz BioNTech a\u015f\u0131lar\u0131n\u0131 olmalar\u0131 \u00f6nerilir.<\/p>\n 2.\u00a0Hi\u00e7 a\u015f\u0131lanmam\u0131\u015f ki\u015filere mRNA a\u015f\u0131s\u0131 yap\u0131l(a)mad\u0131\u011f\u0131 durumda*Sinovac a\u015f\u0131s\u0131 ile \u00fc\u00e7 doz (0, 1 ve 4. aylarda) a\u015f\u0131laman\u0131n ard\u0131ndan en erken 3 ay sonra hat\u0131rlatma dozunu (yap\u0131labiliyorsa BioNTech a\u015f\u0131s\u0131 ile) olmalar\u0131 \u00f6nerilir.<\/p>\n 3.\u00a0\u00c7e\u015fitli nedenlerle primer a\u015f\u0131 \u015femas\u0131 (Sinovac i\u00e7in 0,1, 4. aylarda 3 doz, BioNTech i\u00e7in bir ay arayla iki doz) yar\u0131m kalan ki\u015filerin a\u015f\u0131lamalar\u0131na kald\u0131klar\u0131 yerden devam edilmesi, hat\u0131rlatma dozlar\u0131n\u0131n primer \u015feman\u0131n tamamlanmas\u0131ndan en erken 3 ay sonra yap\u0131lmas\u0131 \u00f6nerilir.<\/p>\n 4.\u00a0\u0130ki doz BioNTech a\u015f\u0131s\u0131 olmu\u015f ki\u015filerin 2. dozdan en erken 3 ay sonra hat\u0131rlatma dozunu olmalar\u0131 \u00f6nerilir.<\/p>\n 5.\u00a0\u00dc\u00e7 doz Sinovac a\u015f\u0131s\u0131 olmu\u015f ki\u015filerin son dozdan en erken 3 ay sonra hat\u0131rlatma dozlar\u0131n\u0131 (tercihen BioNTech a\u015f\u0131s\u0131 ile) olmalar\u0131 \u00f6nerilir.<\/p>\n 6.\u00a0\u0130ki doz Sinovac ard\u0131ndan bir doz BioNTech a\u015f\u0131s\u0131 olanlar\u0131n, son a\u015f\u0131dan en erken 3 ay sonra ikinci doz BioNTech a\u015f\u0131lar\u0131n\u0131 olmalar\u0131 \u00f6nerilir.<\/p>\n 50 YA\u015eIN \u00dcZER\u0130NDE OLANLAR<\/strong><\/p>\n 7. \u0130ki doz Sinovac ard\u0131ndan iki doz BioNTech a\u015f\u0131s\u0131 (toplam 4 doz a\u015f\u0131) olanlar i\u00e7erisinde 50 ya\u015f\u0131n \u00fczerinde olanlar, hastal\u0131k veya ilaca ba\u011fl\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k yetersizli\u011fi olanlar, altta yatan ciddi hastal\u0131\u011f\u0131 (diyaliz uygulananlar, kalp yetmezli\u011fi, ileri AC yetmezli\u011fi ve siroz) bulunanlar ve y\u00fcksek miktarda virusla kar\u015f\u0131la\u015fma riski olan ki\u015filer (sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131) hat\u0131rlatma dozunu, son a\u015f\u0131dan en erken 3 ay sonradan itibaren olabilirler. Bu gruplar d\u0131\u015f\u0131nda kalan ki\u015filerde a\u015f\u0131lar\u0131n a\u011f\u0131r hastal\u0131k ve \u00f6l\u00fcmden koruyucu etkisi devam etti\u011finden hat\u0131rlatma dozunu olmalar\u0131na \u015fimdiki bilgilere g\u00f6re gerek yoktur. \u00d6neriler, yeni veriler \u0131\u015f\u0131\u011f\u0131nda de\u011ferlendirilmelidir.<\/p>\n 8.\u00a0Daha \u00f6nce \u00fc\u00e7 doz BioNTech a\u015f\u0131s\u0131 olanlar i\u00e7erisinde 50 ya\u015f\u0131n \u00fczerinde olanlar, hastal\u0131k veya ilaca ba\u011fl\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k yetersizli\u011fi olanlar, altta yatan ciddi hastal\u0131\u011f\u0131 (diyaliz uygulananlar, kalp yetmezli\u011fi, ileri AC yetmezli\u011fi ve siroz) bulunanlar ve y\u00fcksek miktarda virusla kar\u015f\u0131la\u015fma riski olan ki\u015filer (sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131) hat\u0131rlatma dozunu, son a\u015f\u0131dan en erken 3 ay sonradan itibaren olabilirler. Bu gruplar d\u0131\u015f\u0131nda kalan ki\u015filerde a\u015f\u0131lar\u0131n a\u011f\u0131r hastal\u0131k ve \u00f6l\u00fcmden koruyucu etkisi devam etti\u011finden hat\u0131rlatma dozunu olmalar\u0131na \u015fimdiki bilgilere g\u00f6re gerek yoktur. \u00d6neriler, yeni veriler \u0131\u015f\u0131\u011f\u0131nda de\u011ferlendirilmelidir.<\/p>\n 9.\u00a0\u00d6nceki varyantlarla (\u00fclkemiz i\u00e7in 1 Ocak 2022 \u00f6ncesinde) hastal\u0131k ge\u00e7irdikten sonra bir doz BioNTech olmu\u015f ki\u015filere, Omikrona ve di\u011fer varyantlara kar\u015f\u0131 uzun s\u00fcre korunduklar\u0131 i\u00e7in, \u015fimdiki bilgilere g\u00f6re ek hat\u0131rlatma dozuna gerek yoktur. Yeni veriler \u0131\u015f\u0131\u011f\u0131nda de\u011ferlendirilmelidir.<\/p>\n 10.\u00a0\u00d6nceki varyantlarla (\u00fclkemiz i\u00e7in 1 Ocak 2022 \u00f6ncesinde) hastal\u0131k ge\u00e7irdikten sonra bir doz Sinovac olanlar\u0131n, son Sinovac’tan 3 ay sonra (tercihen BioNTech ile) bir hat\u0131rlatma dozu olmalar\u0131 \u00f6nerilir.<\/p>\n 11.\u00a0\u0130ki doz BioNTech olmas\u0131na ra\u011fmen herhangi bir varyantla hastal\u0131k ge\u00e7irmi\u015f olan ki\u015filerin hastal\u0131ktan 6 ay sonra bir doz BioNTech a\u015f\u0131s\u0131 olmalar\u0131 \u00f6nerilir. B\u00f6ylelikle a\u015f\u0131 sonras\u0131nda Omikrona kar\u015f\u0131 en az 6 ay yeterli koruma sa\u011flanacakt\u0131r. Bu ki\u015filerin yeni bir varyant \u00e7\u0131kmad\u0131\u011f\u0131 s\u00fcrece hat\u0131rlatma dozu olmalar\u0131na \u015fimdiki bilgilere g\u00f6re gerek yoktur. Alt\u0131nc\u0131 ay\u0131n sonunda yeni veriler \u0131\u015f\u0131\u011f\u0131nda de\u011ferlendirilmelidir.<\/p>\n 12. A\u015f\u0131 \u015femas\u0131 tamamlanmadan veya hi\u00e7 a\u015f\u0131lanmadan \u00f6nceki varyantlarla (\u00fclkemiz i\u00e7in 1 Ocak 2022 \u00f6ncesinde) hastal\u0131k ge\u00e7irmi\u015f olan ki\u015filerin, hastal\u0131ktan en erken 3 ay sonra (tercihen 6. Ayda) tek doz BioNTech a\u015f\u0131s\u0131 olmalar\u0131, mRNA a\u015f\u0131s\u0131 yap\u0131l(a)mad\u0131\u011f\u0131 durumda iki doz Sinovac a\u015f\u0131s\u0131 ile (0 ve 1. aylarda) a\u015f\u0131lanmalar\u0131 \u00f6nerilir.<\/p>\n DELTA UYARISI<\/strong><\/p>\n 13.\u00a0A\u015f\u0131 \u015femas\u0131 tamamlanmadan veya hi\u00e7 a\u015f\u0131lanmadan Omikron ile (\u00fclkemiz i\u00e7in 1 Ocak 2022 sonras\u0131nda) hastal\u0131k ge\u00e7irmi\u015f olan ki\u015filerin (Delta varyant\u0131na yeterli ba\u011f\u0131\u015f\u0131kl\u0131klar\u0131 olmayaca\u011f\u0131 i\u00e7in) hastal\u0131ktan 3 ay sonra ba\u015flamak \u00fczere 1 ay arayla iki doz BioNTech a\u015f\u0131s\u0131 olmalar\u0131 \u00f6nerilir. mRNA a\u015f\u0131s\u0131 yap\u0131l(a)mad\u0131\u011f\u0131 durumda*Sinovac a\u015f\u0131s\u0131 ile \u00fc\u00e7 doz (0, 1 ve 4. aylarda) a\u015f\u0131lanmalar\u0131 \u00f6nerilir.<\/p>\n 14.\u00a0\u0130ki doz Sinovac ard\u0131ndan 2 doz BioNTech a\u015f\u0131s\u0131 veya 3 doz BioNTech a\u015f\u0131s\u0131 veya 4 doz BioNTech a\u015f\u0131s\u0131 uyguland\u0131ktan sonra COVID-19 ge\u00e7irmi\u015f ki\u015filere hat\u0131rlatma dozu yap\u0131lmas\u0131na eldeki verilere g\u00f6re gerek yoktur.<\/p>\n 15.\u00a0Ba\u011f\u0131\u015f\u0131kl\u0131k yetmezli\u011fi olan ki\u015filerin inaktif a\u015f\u0131 yerine mRNA a\u015f\u0131lar\u0131 ile a\u015f\u0131lanmalar\u0131 \u00f6nerilir. Bu ki\u015filer 1 ay arayla 3 dozdan (BioNTech) olu\u015fan primer a\u015f\u0131 \u015femas\u0131n\u0131 tamamlad\u0131ktan 3 ay sonra birinci ek dozlar\u0131n\u0131 (4. a\u015f\u0131lar\u0131n\u0131) , bundan en az 4 ay sonra da ikinci ek dozlar\u0131n\u0131 (5. a\u015f\u0131lar\u0131n\u0131) olmal\u0131d\u0131rlar. Bundan farkl\u0131 \u015femalar uygulanm\u0131\u015f ise ek dozlar\u0131n say\u0131s\u0131 ve zamanlamas\u0131n\u0131n belirlenmesi i\u00e7in \u0130nfeksiyon Hastal\u0131klar\u0131 ve Klinik Mikrobiyoloji uzmanlar\u0131na ba\u015fvurmalar\u0131 \u00f6nerilir.<\/p>\n 16.\u00a0Mevcut veriler \u0131\u015f\u0131\u011f\u0131nda, d\u00f6rt doz BioNTech veya \u0130ki doz SinoVac sonras\u0131nda 3 doz BioNTech a\u015f\u0131s\u0131 olmu\u015f ki\u015filerin ba\u011f\u0131\u015f\u0131kl\u0131k yetmezli\u011fi olmad\u0131\u011f\u0131 s\u00fcrece hat\u0131rlatma dozu olmalar\u0131na gerek bulunmamaktad\u0131r. Bu ki\u015filerde varyantlar\u0131 da i\u00e7eren polivalan a\u015f\u0131larla ek dozlar\u0131n gereklili\u011fi konusunda \u00e7al\u0131\u015fmalar devam etmektedir.<\/p>\n","protected":false},"excerpt":{"rendered":" Coronada vaka say\u0131lar\u0131 artarken uzmanlardan da art arda uyar\u0131lar geliyor. T\u00fcrkiye Klinik Mikrobiyoloji ve \u0130nfeksiyon Hastal\u0131klar\u0131 Derne\u011fi KL\u0130M\u0130K …<\/p>\n","protected":false},"author":1,"featured_media":6190,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[30],"tags":[180,2043,1297,181,2044],"class_list":["post-6189","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-saglik","tag-asi","tag-biontech","tag-doz","tag-hastalik","tag-olanlar"],"_links":{"self":[{"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/posts\/6189","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6189"}],"version-history":[{"count":1,"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/posts\/6189\/revisions"}],"predecessor-version":[{"id":6191,"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/posts\/6189\/revisions\/6191"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/media\/6190"}],"wp:attachment":[{"href":"https:\/\/haberulus.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6189"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6189"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}